Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 1, p. 45, doi. 10.3390/jcm8010045
- By:
- Publication type:
- Article
Works by Milder, Tamara Y.
Results: 15
1
2
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 997, doi. 10.1111/dom.16061
- By:
- Publication type:
- Article
3
Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2787, doi. 10.1111/dom.15597
- By:
- Publication type:
- Article
4
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.
- Published in:
- Drug Safety, 2020, v. 43, n. 12, p. 1211, doi. 10.1007/s40264-020-01010-6
- By:
- Publication type:
- Article
5
Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022.
- Published in:
- British Journal of Clinical Pharmacology, 2025, v. 91, n. 1, p. 117, doi. 10.1111/bcp.16231
- By:
- Publication type:
- Article
6
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 11, p. 1481, doi. 10.1007/s00228-019-02732-y
- By:
- Publication type:
- Article
7
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium‐glucose cotransporter 2 inhibitor initiation.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 4, p. 559, doi. 10.1111/imj.16203
- By:
- Publication type:
- Article
8
Should the cardio‐protective properties of sodium‐glucose cotransporter 2 inhibitors dictate therapeutic decision‐making in patients with type 2 diabetes.
- Published in:
- Internal Medicine Journal, 2020, v. 50, n. 5, p. 645, doi. 10.1111/imj.14819
- By:
- Publication type:
- Article
9
Gastric ultrasound and mitigating risk of glucagon‐like peptide‐1 receptor agonists: a reply.
- Published in:
- Anaesthesia, 2024, v. 79, n. 10, p. 1133, doi. 10.1111/anae.16369
- By:
- Publication type:
- Article
10
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice.
- Published in:
- Anaesthesia, 2024, v. 79, n. 7, p. 735, doi. 10.1111/anae.16306
- By:
- Publication type:
- Article
11
Sodium-Glucose Cotransporter 2 Inhibitor-Associated "Ketoacidosis" Versus "Diabetic Ketoacidosis": The Importance of Accurate Terminology.
- Published in:
- Drug Safety, 2023, v. 46, n. 12, p. 1303, doi. 10.1007/s40264-023-01358-5
- By:
- Publication type:
- Article
12
Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
13
Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: engagement with information and perceptions of risk.
- Published in:
- Age & Ageing, 2011, v. 40, n. 2, p. 254, doi. 10.1093/ageing/afq160
- By:
- Publication type:
- Article
14
Preoperative GLP-1 Receptor Agonists and Risk of Postoperative Respiratory Complications.
- Published in:
- 2024
- By:
- Publication type:
- Letter
15
'It looks after me': How older patients make decisions about analgesics for osteoarthritis.
- Published in:
- Arthritis Care & Research, 2011, v. 63, n. 9, p. 1280, doi. 10.1002/acr.20514
- By:
- Publication type:
- Article